Management's Discussion and Analysis of Financial Condition and Results of Operations

Strategic Insights -

Our company's late-stage programs, including the CGRP Platform Study 303 in the Middle East & Gulf Countries and Israel, and Phase 2/3 bridging studies in Japan, are progressing as planned. The Pharmaceuticals and Medical Devices Agency (PMDA) has been engaged to guide the development of our product in Japan, with initiation of the bridging studies anticipated to begin in the fourth quarter of 2021. We have also entered into a collaboration with Pfizer, which was initiated in November 2021. Our actual results and timing of certain events may differ materially from the results discussed, projected, anticipated, or indicated in any forward-looking statements.

Key Takeaways:

  • Our late-stage programs include the CGRP Platform Study 303 in the Middle East & Gulf Countries and Israel, and Phase 2/3 bridging studies in Japan, which are anticipated to begin in the fourth quarter of 2021.
  • We have engaged the Pharmaceuticals and Medical Devices Agency (PMDA) to guide the development of our product in Japan.
  • Our collaboration with Pfizer was initiated in November 2021 and involves the issuance and sale of common shares to Pfizer.
  • Our actual results and timing of certain events may differ materially from the results discussed, projected, anticipated, or indicated in any forward-looking statements.
  • We have disclaimed any obligation to update or revise any forward-looking statements to reflect changes in our expectations or in events, conditions, or circumstances.

Statistics:

  • Our collaboration with Pfizer was initiated in November 2021.
  • The bridging studies in Japan are anticipated to begin in the fourth quarter of 2021.
  • Our late-stage programs include the CGRP Platform Study 303 in the Middle East & Gulf Countries and Israel.
  • We have engaged the Pharmaceuticals and Medical Devices Agency (PMDA) to guide the development of our product in Japan.

Sources:

  • (SEC) -- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
  • COMTEX -- November 09, 2021
  • COMTEX_396602125/2041/2021-11-09T17:35:31
  • (c) 1995-2021 Cybernet Data Systems, Inc. All Rights Reserved